(UroToday.com) The 2021 European Society of Medical Oncology’s (EMSO) annual congress included a proffered paper session in non-prostate genitourinary tumors, as well as a discussant presentation by Dr. Brian Rini discussing maintaining efficacy and improving quality of life in the delivery of RCC therapy. Dr. Rini discussed three excellent abstracts: “Pembrolizumab versus placebo as adjuvant therapy for patients with RCC: Patient-reported outcomes (PROs) in KEYNOTE-564” by Dr. Toni Choueiri, “Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced RCC: A randomized phase II trial (PRISM)” by Dr. Naveen Vasudev, and “STAR: A Randomized Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the treatment of locally advanced and/or metastatic RCC” by Dr. Janet Brown.